Fareston Indications, Dosage, Storage, Stability - Toremifene

Fareston Indications, Dosage, Storage, Stability - Toremifene

INDICATIONS

FARESTON is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.

The dosage of FARESTON is 60 mg, once daily, orally. Treatment is generally continued until disease progression is observed.

FARESTON Tablets, containing toremifene citrate in an amount equivalent to 60 mg of toremifene, are round, convex, unscored, uncoated, and white, or almost white.

FARESTON Tablets are identified with TO 60 embossed on one side.

FARESTON Tablets are available as:

NDC 54092-170-30 bottles of 30

NDC 54092-170-01 bottles of 100

Store at 25°C (77°F) excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Protect from heat and light.

Developed and Manufactured by
Orion Corporation, Espoo, Finland

Distributed by Shire US Inc.
Newport, KY 41071, USA
under license from Orion Corporation.
Product covered by Orion Product Patents and related patent numbers.
© 2001 Shire US Inc.
All rights reserved.